

Liquid-based cytology
Computer-guided screening
Immuno-chemistry



Helping all people
live healthy lives



Find what you are looking for

Rely on the FDA-approved
BD FocalPoint™ GS Imaging System
for efficient and optimal interpretation
of your slides




Rely on the FDA-approved **BD FocalPoint™ GS Imaging System** for assistance in your cervical cancer screening routine.

1. Reduced false negatives through the detection of significantly more dysplasia ⁽¹⁾

BD FocalPoint™ GS Imaging System shows superior dysplasia detection for BD SurePath™ Liquid-based cytology and conventional Pap smears as compared to the actual practice. (2-3-4-5-6-7). A FDA-approved clinical trial, comparing the **BD FocalPoint™ GS Imaging System** with manual screening of BD SurePath™ Pap test slides, found a:

- 24.5% increase in Cancer sensitivity
- 19.6% increase in HSIL +sensitivity
- 9.8% increase in LSIL+ sensitivity
- 9.2% increase in ASC-H+ sensitivity

2. Reduced unnecessary and inconvenient repeat testing by lowering your ASC-US result



3. Significantly increased productivity

- Only a limited number of fields of view,
- Up to 25% of the slides can be archived directly (optional)
- Up to 170 slides in an 8-hour work day
- Multiple possibilities to integrate LIS capabilities to accelerate data sharing
- Remote connectivity

References:

- (1) Package insert of BD FocalPoint™ GS Imaging System.
- (2) Wilbur DC., Parker EM., Foti JA. Location-Guided Screening of Liquid-Based Cervical Cytology Specimens. A Potential Improvement in Accuracy and Productivity is Demonstrated in a Preclinical Feasibility Trial. *Am J Clin Path* 2002;118:399-407.
- (3) Passamonti B., Bulletti S., Camilli M., D'Amico M., Di Dato E., Gustinuchi D., Martinelli N., Malaspina M., Spitta N. Evaluation of the FocalPoint GS System Performance in an Italian Population-Based Screening of Cervical Abnormalities. *Acta Cytologica* 2007;51(6):865-871.
- (4) Huang TW., Lin TS., Lee JS. Sensitivity studies of the AutoPap System Location Guided Screening of cervical-vaginal cytologic smears. *Acta Cytologica* 1999;43:363-368.
- (5) Bentz JS. Liquid-based cytology for cervical cancer screening. *Future Drugs* 2005; 5(6), 857-871.
- (6) Lee JS., Kuan L., Oh S., Patten F., Wilbur DC. A feasibility study of the AutoPap System Location Guided Screening. *Acta Cytologica* 1998;42:221-226.
- (7) Kardos T. The FocalPoint System: FocalPoint slide profiler and FocalPoint GS. *Cancer Cytopathology*. Dec 2004.



BD Diagnostics TriPath

Erembodegem-dorp 86
9320 Erembodegem, Belgium
For Europe, Middle East and Africa
Phone: +32 53 720 211
Email: TriPathEurope@BD.com
www.bd.com/TriPath

Product availability has to be confirmed by your local representative.

BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2009 BD. XEUR5115-09.
Becton Dickinson GmbH Tullastrasse 8-12, D-69126 Heidelberg. Sitz: Heidelberg. Geschäftsführer: Matthias Borst.
Amtsgericht Mannheim HRB 330 707.